An analysis of clinical responses on the function of the tumor with respect to PD-L1 positivity showed that a PD-L1 CPS of ≥ 1 is an appropriate cutoff and predictive biomarker of pembrolizumab efficacy [99]. Here, CD274 is linked to neoplasm.